FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223929596> ?p ?o ?g. }

• W4223929596 endingPage "e0266438" @default.
• W4223929596 startingPage "e0266438" @default.
• W4223929596 abstract "Despite progress on population-level HIV viral suppression, unknown outcomes amongst people who have initiated antiretroviral therapy (ART) in low- and middle-income countries, commonly referred to as loss to follow-up (LTFU), remains a barrier. The mean global estimate of LTFU is 20%, exceeding the World Health Organization target of <15%. Pervasive predictors associated with LTFU include younger age, low body mass index, low CD4 count, advanced HIV clinical stage and certain ART regimens. In Namibia, ART use by eligible individuals exceeds 85%, surpassing the global average. Nonetheless, LTFU remains a barrier to achieving viral suppression and requires research to elucidate context-specific factors. An observational cohort study was conducted in Namibia in 2012 by administering surveys to individuals who presented for HIV care and initiated ART for the first time. Additional data were collected from routine medical data monitoring systems. Participants classified as LTFU at 12 months were traced to confirm their status. Predictors of LTFU were analyzed using multivariable logistic regression. Of those who presented consecutively to initiate ART, 524 were identified as eligible to enroll in the study, 497 enrolled, and 474 completed the baseline questionnaire. The cohort had mean age 36 years, 39% were male, mean CD4 cell count 222 cells/mm3, 17% were WHO HIV clinical stage III-IV, and 14% started efavirenz-based regimens. Tracing participants classified as LTFU yielded a re-categorization from 27.8% (n = 132) to 14.3% (n = 68) LTFU. In the final multivariable model, factors associated with confirmed LTFU status were: younger age (OR 0.97, 95% CI 1.00-1.06, p = 0.02); male sex (OR 2.34, CI 1.34-4.06, p = 0.003); difficulty leaving work or home to attend clinic (OR 2.55, CI 1.40-4.65, p = 0.002); and baseline efavirenz-based regimen (OR 2.35, CI 1.22-4.51, p = 0.01). Interventions to reduce LTFU should therefore target young men, particularly those who report difficulty leaving work or home to attend clinic and are on an efavirenz-based regimen." @default.
• W4223929596 created "2022-04-19" @default.
• W4223929596 creator A5031447815 @default.
• W4223929596 creator A5043839359 @default.
• W4223929596 creator A5052083685 @default.
• W4223929596 creator A5058615857 @default.
• W4223929596 creator A5064516016 @default.
• W4223929596 creator A5065541345 @default.
• W4223929596 creator A5079624543 @default.
• W4223929596 creator A5089516926 @default.
• W4223929596 date "2022-04-14" @default.
• W4223929596 modified "2023-09-27" @default.
• W4223929596 title "Predictors of loss to follow-up from HIV antiretroviral therapy in Namibia" @default.
• W4223929596 cites W1494755209 @default.
• W4223929596 cites W1973854903 @default.
• W4223929596 cites W1985329916 @default.
• W4223929596 cites W1987136336 @default.
• W4223929596 cites W1989307318 @default.
• W4223929596 cites W1998660799 @default.
• W4223929596 cites W1998725017 @default.
• W4223929596 cites W2042706402 @default.
• W4223929596 cites W2055351311 @default.
• W4223929596 cites W2055868383 @default.
• W4223929596 cites W2064590924 @default.
• W4223929596 cites W2064881663 @default.
• W4223929596 cites W2065293221 @default.
• W4223929596 cites W2068729701 @default.
• W4223929596 cites W2077053280 @default.
• W4223929596 cites W2082232366 @default.
• W4223929596 cites W2084586254 @default.
• W4223929596 cites W2093404763 @default.
• W4223929596 cites W2109235878 @default.
• W4223929596 cites W2122050550 @default.
• W4223929596 cites W2124801504 @default.
• W4223929596 cites W2139894829 @default.
• W4223929596 cites W2143984072 @default.
• W4223929596 cites W2148158699 @default.
• W4223929596 cites W2159770800 @default.
• W4223929596 cites W2160888326 @default.
• W4223929596 cites W2168895952 @default.
• W4223929596 cites W2530226112 @default.
• W4223929596 cites W2578556124 @default.
• W4223929596 cites W2598671106 @default.
• W4223929596 cites W2604339437 @default.
• W4223929596 cites W2767089427 @default.
• W4223929596 cites W2789423040 @default.
• W4223929596 cites W2807247400 @default.
• W4223929596 doi "https://doi.org/10.1371/journal.pone.0266438" @default.
• W4223929596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35421126" @default.
• W4223929596 hasPublicationYear "2022" @default.
• W4223929596 type Work @default.
• W4223929596 citedByCount "1" @default.
• W4223929596 countsByYear W42239295962023 @default.
• W4223929596 crossrefType "journal-article" @default.
• W4223929596 hasAuthorship W4223929596A5031447815 @default.
• W4223929596 hasAuthorship W4223929596A5043839359 @default.
• W4223929596 hasAuthorship W4223929596A5052083685 @default.
• W4223929596 hasAuthorship W4223929596A5058615857 @default.
• W4223929596 hasAuthorship W4223929596A5064516016 @default.
• W4223929596 hasAuthorship W4223929596A5065541345 @default.
• W4223929596 hasAuthorship W4223929596A5079624543 @default.
• W4223929596 hasAuthorship W4223929596A5089516926 @default.
• W4223929596 hasBestOaLocation W42239295961 @default.
• W4223929596 hasConcept C126322002 @default.
• W4223929596 hasConcept C142462285 @default.
• W4223929596 hasConcept C144024400 @default.
• W4223929596 hasConcept C149923435 @default.
• W4223929596 hasConcept C151730666 @default.
• W4223929596 hasConcept C151956035 @default.
• W4223929596 hasConcept C187212893 @default.
• W4223929596 hasConcept C201903717 @default.
• W4223929596 hasConcept C205545832 @default.
• W4223929596 hasConcept C2779343474 @default.
• W4223929596 hasConcept C2781432083 @default.
• W4223929596 hasConcept C2908647359 @default.
• W4223929596 hasConcept C2993143319 @default.
• W4223929596 hasConcept C3013748606 @default.
• W4223929596 hasConcept C512399662 @default.
• W4223929596 hasConcept C71924100 @default.
• W4223929596 hasConcept C72563966 @default.
• W4223929596 hasConcept C86803240 @default.
• W4223929596 hasConcept C99454951 @default.
• W4223929596 hasConceptScore W4223929596C126322002 @default.
• W4223929596 hasConceptScore W4223929596C142462285 @default.
• W4223929596 hasConceptScore W4223929596C144024400 @default.
• W4223929596 hasConceptScore W4223929596C149923435 @default.
• W4223929596 hasConceptScore W4223929596C151730666 @default.
• W4223929596 hasConceptScore W4223929596C151956035 @default.
• W4223929596 hasConceptScore W4223929596C187212893 @default.
• W4223929596 hasConceptScore W4223929596C201903717 @default.
• W4223929596 hasConceptScore W4223929596C205545832 @default.
• W4223929596 hasConceptScore W4223929596C2779343474 @default.
• W4223929596 hasConceptScore W4223929596C2781432083 @default.
• W4223929596 hasConceptScore W4223929596C2908647359 @default.
• W4223929596 hasConceptScore W4223929596C2993143319 @default.
• W4223929596 hasConceptScore W4223929596C3013748606 @default.
• W4223929596 hasConceptScore W4223929596C512399662 @default.
• W4223929596 hasConceptScore W4223929596C71924100 @default.

• next